New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine

 New Brunswick Government Introduces Biosimilars Switch Policy to Improve Patient Access to Safe and Effective Medicine

Shots:

  • New Brunswick joins British Columbia and Alberta in implementing a “switch” policy that changes coverage for specific biologic medicines
  • Patients switching from reference biologics to biosimilar versions will continue receiving safe, effective treatment and will enable to save millions of dollars once implemented
  • Sandoz is committed to supporting patients, their HCPs, and the New Brunswick Government with high quality biosimilar medicines and experienced, comprehensive patient support programs

Click here to­ read full press release/ article | Ref: Sandoz | Image: Sandoz

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post